医学
蛋白尿
肾功能
内科学
狼疮性肾炎
随机对照试验
达帕格列嗪
肾脏疾病
泌尿科
安慰剂
尿检
泌尿系统
临床终点
肾病
胃肠病学
糖尿病
系统性红斑狼疮
肾
肌酐
临床试验
析因分析
作者
Nourelsabah Mohamed,Karem N Zayed,Muhammed Ahmed Elhadedy,Mohamed Hosney Badawi,Wael Ibrahim Mortada,Kareem A. Nabieh,Mohamed Abdel kader Sobh,Ayman Fathy Refaie
出处
期刊:Ndt Plus
[Oxford University Press]
日期:2026-07-10
卷期号:19 (8): sfag231-sfag231
被引量:1
摘要
Background: Lupus nephritis (LN) remains a major cause of chronic kidney disease (CKD) and end-stage renal disease despite advances in immunosuppressive therapy. Sodium-glucose cotransporter-2 (SGLT2) inhibitors confer renal protection in diabetic and nondiabetic CKD and have been associated with increases in hemoglobin levels, but their renal and hematologic effects in immune-mediated glomerulopathies such as LN are not well defined. Objective: To evaluate the renal and hematologic effects, efficacy, and safety of dapagliflozin as adjunctive therapy in patients with LN. Methods: = 41) for 12 months in addition to standard immunosuppressive therapy. The primary renal endpoint was percentage change in 24-h urinary protein excretion. Secondary renal outcomes included change in eGFR. Hematologic parameters assessed at baseline and 12 months included hemoglobin, erythropoietin, hepcidin, ferritin, and transferrin saturation. The primary analysis used analysis of covariance (ANCOVA) with adjustment for baseline values and clinically relevant covariates including age and background immunosuppressive therapy. Sensitivity analyses using log-transformed proteinuria were also performed. Additional analyses evaluated adjusted 12-month eGFR and eGFR slope. Results: At 12 months, dapagliflozin was associated with a numerical reduction in proteinuria compared with placebo; however, this difference did not reach statistical significance. Adjusted analyses using ANCOVA confirmed the absence of a significant treatment effect. No significant differences were observed in eGFR, eGFR slope, or hematologic parameters. Conclusion: In this randomized controlled trial, dapagliflozin was associated with a numerical reduction in proteinuria that did not reach statistical significance after adjustment for baseline characteristics and background immunosuppressive therapy. No significant effect on kidney function, eGFR slope, or hematologic parameters was observed. These findings suggest a possible signal that requires confirmation in larger, adequately powered, longer-duration studies.Clinical trials registration number: NCT05748925 (ClinicalTrials.gov). Registered 28 February 2023-Retrospectively registered (https://register.clinicaltrials.gov/prs/beta/studies/S000CWI200000138/recordSummary).
科研通智能强力驱动
Strongly Powered by AbleSci AI